江南·体育(JN SPORTS)官方网站,江南体育app下载

|
|
EN
  • 业务咨询

    中国:

    Email: marketing@hangzhouaijunshengwu.com

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换

搜索结果包含 Cell Rep:古老病毒或可作为基因疗法的载体 的内容

Aug 21,2023
TAK-931是一种高效的CDC7抑制剂,通过抑制CDC7来抑制DNA复制,具有抗肿瘤功效,体内药效研究通过美迪西进行
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell divis
查看更多
TAK-931是一种高效的CDC7抑制剂,通过抑制CDC7来抑制DNA复制,具有抗肿瘤功效,体内药效研究通过美迪西进行
Jul 06,2023
IAP蛋白是有吸引力的癌症治疗靶点。SM-406 是一种口服有效的IAP拮抗剂。SM-406 在雄性SD大鼠、比格犬和NHP中的PK研究通过美迪西进行
Apoptosis is a cellular process critical to the normal development and homeostasis of multicellular organisms. The inhibitor of apoptosis proteins (IAPs) are a class of key apoptosis regulators.
查看更多
IAP蛋白是有吸引力的癌症治疗靶点。SM-406 是一种口服有效的IAP拮抗剂。SM-406 在雄性SD大鼠、比格犬和NHP中的PK研究通过美迪西进行
Jul 06,2023
设计合成一系列用于治疗胃癌的多靶点受体酪氨酸激酶抑制剂,并进行生物学评价。其中药代动力学分析通过美迪西进行
Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric c
查看更多
设计合成一系列用于治疗胃癌的多靶点受体酪氨酸激酶抑制剂,并进行生物学评价。其中药代动力学分析通过美迪西进行
Jul 06,2023
AD80是一种多激酶抑制剂,在多种肝细胞癌临床前动物模型中具有抗肿瘤活性,AD80在血浆中的含量通过美迪西进行LC-MS/MS测定
Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models
查看更多
AD80是一种多激酶抑制剂,在多种肝细胞癌临床前动物模型中具有抗肿瘤活性,AD80在血浆中的含量通过美迪西进行LC-MS/MS测定
Jul 06,2023
氯磺丙脲对蠕虫和人肺成纤维细胞MRC-5细胞具有抗衰老作用,氯磺丙脲在小鼠中的生物利用度测定通过美迪西进行
Sulfonylureas exert their anti-diabetic effects by inhibiting K-ATP channels in the plasma membrane of islet β-cells. Chlorpropamide acts on complex II directly or indirectly via mitoK-ATP to produce
查看更多
氯磺丙脲对蠕虫和人肺成纤维细胞MRC-5细胞具有抗衰老作用,氯磺丙脲在小鼠中的生物利用度测定通过美迪西进行
Jul 06,2023
SKLB-YTH-60可改善博来霉素诱导的肺纤维化小鼠模型中的炎症和纤维化,YTH-60的体内药代动力学研究通过美迪西进行
Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through
查看更多
SKLB-YTH-60可改善博来霉素诱导的肺纤维化小鼠模型中的炎症和纤维化,YTH-60的体内药代动力学研究通过美迪西进行
Jul 05,2023
阿帕替尼通过VEGFR2通路抑制紫杉醇对胃癌细胞的耐药性
Overexpression of VEGFR2 can offset the rescue effect of Apatinib on Paclitaxel-induced drug resistance of MGC803 cells. Apatinib inhibits Paclitaxel resistance of MGC803 cells via the VEGFR2 #signali
查看更多
阿帕替尼通过VEGFR2通路抑制紫杉醇对胃癌细胞的耐药性
Jul 05,2023
研究人员报告了一种具有细胞渗透性的选择性METTL3纳摩尔抑制剂UZH1a,作者感谢美迪西合成了UZH1a和UZH1b
The methylase METTL3 is the writer enzyme of the N6‐methyladenosine (m6A) modification of RNA.Here researchers report a nanomolar inhibitor of METTL3 (UZH1a) which is selective and cell‐permeable, whi
查看更多
研究人员报告了一种具有细胞渗透性的选择性METTL3纳摩尔抑制剂UZH1a,作者感谢美迪西合成了UZH1a和UZH1b
Jul 05,2023
RIPK2激酶参与多种慢性炎症,UH15-15抑制RIPK2激酶并具有良好的体外ADME和PK特性,PK研究通过美迪西进行
Receptor interacting protein kinase-2 (#RIPK2) is an enzyme involved in the transduction of pro-inflammatory nucleotide-binding oligomerization domain cell signaling, a pathway implicated in numerous
查看更多
RIPK2激酶参与多种慢性炎症,UH15-15抑制RIPK2激酶并具有良好的体外ADME和PK特性,PK研究通过美迪西进行
Jul 05,2023
合成具有体内抗肿瘤活性的强效PD-L1抑制剂,并进行生物学评价和机制研究。PK研究通过美迪西进行
PD-1 and PD-L1 have been very successful for the treatment of various tumors, including NSCLC, urothelial cancer, melanoma, head and neck squamous cell cancer, and lymphoma. Researchers identified com
查看更多
合成具有体内抗肿瘤活性的强效PD-L1抑制剂,并进行生物学评价和机制研究。PK研究通过美迪西进行
Jul 05,2023
zapERtrap:光调节的内质网释放系统揭示了意想不到的神经元运输途径,Zapalog的合成通过美迪西进行
zapERtrap opens the door to previously unapproachable questions concerning how proteins are processed, trafficked, and secreted in space and time in complex cellular environments. zapERtrap relies on
查看更多
zapERtrap:光调节的内质网释放系统揭示了意想不到的神经元运输途径,Zapalog的合成通过美迪西进行
Jul 05,2023
研究人员使用RZ-2994来表征抑制SHMT1/2在T细胞急性淋巴细胞白血病 (T-ALL) 中的作用,RZ-2994通过美迪西定制合成
Despite progress in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Researchers used SHMT1/2 inh
查看更多
研究人员使用RZ-2994来表征抑制SHMT1/2在T细胞急性淋巴细胞白血病 (T-ALL) 中的作用,RZ-2994通过美迪西定制合成
Jul 05,2023
研究人员开发了一种高特异性的CDC7抑制剂TAK-931作为临床肿瘤治疗剂,抗肿瘤药效研究通过美迪西进行
Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy s
查看更多
研究人员开发了一种高特异性的CDC7抑制剂TAK-931作为临床肿瘤治疗剂,抗肿瘤药效研究通过美迪西进行
Jul 05,2023
设计、合成和评估具有体内抗炎活性的RIPK1抑制剂,PK研究通过美迪西进行
RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, researchers r
查看更多
设计、合成和评估具有体内抗炎活性的RIPK1抑制剂,PK研究通过美迪西进行
Jun 28,2023
ARD-2128是一种PROTAC AR降解剂,具有出色的血浆和微粒体稳定性,体外稳定性和PK研究通过美迪西进行
ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
ARD-2128是一种PROTAC AR降解剂,具有出色的血浆和微粒体稳定性,体外稳定性和PK研究通过美迪西进行
Jun 28,2023
放射疗法用作肺癌的主要治疗方法,在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过美迪西进行
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
查看更多
放射疗法用作肺癌的主要治疗方法,在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过美迪西进行
Jun 28,2023
CAR-T疗法主要针对白血病与恶性淋巴瘤,此研究中构建沉默PD-1的shRNA载体质粒,测序后质粒的鉴定通过美迪西进行
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR i
查看更多
CAR-T疗法主要针对白血病与恶性淋巴瘤,此研究中构建沉默PD-1的shRNA载体质粒,测序后质粒的鉴定通过美迪西进行
Jun 28,2023
GS-5801是一种有效的KDM5抑制剂,具有抗HBV活性,GS-5801通过美迪西合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
查看更多
GS-5801是一种有效的KDM5抑制剂,具有抗HBV活性,GS-5801通过美迪西合成
Jun 28,2023
TR-107是人类线粒体蛋白酶ClpP的有效激活剂,PK分析通过美迪西进行
The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evalsuated for pharmacokinetic
查看更多
TR-107是人类线粒体蛋白酶ClpP的有效激活剂,PK分析通过美迪西进行
Jun 16,2022
美迪西邀您相聚SAPA美国2022细胞&基因治疗年会
美迪西陈春麟博士及美国商务团队将于 6 月 17 日至 18 日参加 Cell & Gene Therapy Annual Conference。届时将与参会的众嘉宾进行详细交谈,共同探讨我们的专业服务如何更快地加速各企业的药物研发过程!
查看更多
美迪西邀您相聚SAPA美国2022细胞&基因治疗年会
江南·体育(JN SPORTS)官方网站